Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Radioprotective effects of the anti-cancer preparation NSC 631570 (Ukraine)

2nd World Congress on Radiology and Oncology

Wassil Nowicky

Ukrainian Anti-Cancer Institute, Austria

Keynote: OMICS J Radiol

DOI: 10.4172/2167-7964-C1-020

Abstract
When NSC 631570 has been used in clinic, it was observed that the patients treated with this drug tolerate the concomitant radiotherapy much better. The adverse effects of this aggressive treatment modality were significantly reduced to minimal. This gave reason to study radioprotective properties of NSC 631570 in the in vitro and in vivo tests. The radioprotective effect of NSC 631570 has been confirmed by the infection models in mice where its effect was superior to the effect of the known radioprotector Cysteamine. Compared to other agents, NSC 631570 exerted a strong radioprotective effect similar to such of lymphokinin. These radioprotective properties of NSC 631570 were confirmed in further studies in rats at the Institute of Applied Cell Culture (Munich, Germany). Ukrain normalized the level of nuclear thyroid hormone receptors influenced by short-term, whole body gamma-irradiation of rats with 1 Gy, beginning from the first day after administration of the drug. Thus, authors concluded Ukrain can minimize the consequences of irradiation on the endocrine system of experimental animals. The radio protective effect of NSC 631570 was also studied and confirmed on in vitro models on the human skin firbroblasts HSF1 and HSF2 as well as lung fibroblasts CCD32-LU. Differential effects of NSC 631570 in modulating radiation toxicity of human cancer cell lines and its protective effect in normal human fibroblasts suggest that this agent may be beneficial for clinical radiochemotherapy.
Biography

Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute, Vienna, Austria. He has completed his study at the Radiotechnical Faculty of the Technical, University of Lviv, Ukraine. He is the author of over 300 scientific articles dedicated to cancer research. He is a member of the New York Academy of Sciences, member of the European Union for Applied Immunology and American Association for Scientific Progress, Doctor “Honoris causa” of the Open International University on Complex Medicine in Colombo, Honorary member of the Austrian Society Albert Schweizer. He has received the award for merits of National Guild of Pharmasists of America, the award of Austrian Society of Sanitary, Hygiene and Public Health Services and others.

E-mail: dr.nowicky@yahoo.de

 

Top